pISSN 1226-6051
eISSN 2508-786X

Table. 3.

Table. 3.

Incidence of adverse events: everolimus with low dose tacrolimus group and conventional dose tacrolimus group

EVR+Low TAC (n=40) TAC (n=78) p-value
Incidence of adverse events
Infection, n (%) 7 (17.5) 14 (17.9) 0.952
Oral ulcer, n (%) 6 (15.0) 1 (1.3) 0.006*
Gastrointestinal disorder, n (%)
Diarrhea 10 (25.0) 12 (15.4) 0.204
Nausea 8 (20.0) 13 (16.7) 0.654
Neutropenia, n (%) 18 (45.0) 25 (32.1) 0.167
Grade III neutropenia, n (%) 4 (10.0) 13 (16.7) 0.329
New onset or progression of disease
Hypertension, n (%) 11 (27.5) 14 (17.9) 0.229
Diabetes mellitus, n (%) 9 (22.5) 19 (24.4) 0.822
Decrease of renal function, n (%) 7 (17.5) 28 (35.9) 0.038*
Recurrence of HCC, n (%) 2 (5.0) 1 (1.3) 0.265
Dyslipidemia, n (%) 18 (45.0) 17 (21.8) 0.009*

EVR+Low TAC: everolimus+low dose tacrolimus cohort

TAC: conventional dose tacrolimus cohort HCC: hepatocellular cancer

* p<0.05

Korean J Clin Pharm 2021;31:44-52 https://doi.org/10.24304/kjcp.2021.31.1.44
© 2021 Korean J Clin Pharm